MedTrace Logo

Systemic Immune-Inflamation Index and Mortality in ICU Patients

NCT07493759 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 570

Last updated 2026-03-25

No results posted yet for this study

Summary

Systemic Immune-Inflammation Index (SII) is a hemogram-derived biomarker reflecting the balance between systemic inflammation and immune response. In critically ill patients, inflammatory burden at admission may play a key role in prognosis. This retrospective cohort study aims to evaluate the association between admission SII levels and intensive care unit (ICU) mortality in adult patients admitted to a reanimation ICU. Secondary objectives include comparison of mortality according to infectious versus non-infectious admission diagnoses and assessment of the relationship between SII and established severity scores, including APACHE II and Glasgow Coma Scale (GCS). The findings may support the use of SII as a rapid, inexpensive prognostic marker in critically ill patients.

Conditions

Interventions

OTHER

Systemic Immune-Inflammation Index (SII)

Systemic immune-inflammation index (SII) calculated at intensive care unit admission using routine complete blood count parameters. SII is calculated as platelet count multiplied by neutrophil count divided by lymphocyte count. Patients are classified into high and low SII groups based on a predefined cutoff value. No therapeutic intervention is administered as part of the study.

Sponsors & Collaborators

  • Ataturk University

    lead OTHER

Principal Investigators

  • nazim doğan, MD · Atatürk University Faculty of Medicine, Department of Anesthesiology and Reanimation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-03-18
Completion
2026-03-18

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07493759 on ClinicalTrials.gov